Real-life data regarding acute procedural success and 1-year clinical outcome of desolve bioresorbable scaffolds

dc.authorid0000-0001-5825-8627
dc.authorid0000-0003-1919-3183
dc.authorid0000-0001-9975-5507
dc.authorid0000-0002-4607-5724
dc.authorid0000-0002-4281-0867
dc.authorid0000-0003-0230-6575
dc.authorid0000-0003-2995-8792
dc.authorid0000-0002-4951-6716
dc.contributor.authorGüneş, Hacı Murat
dc.contributor.authorGökdeniz, Tayyar
dc.contributor.authorKızılırmak Yılmaz, Filiz
dc.contributor.authorDemir, Gültekin Günhan
dc.contributor.authorGüler, Ekrem
dc.contributor.authorGüler Babür, Gamze
dc.contributor.authorKaraca, Oğuz
dc.contributor.authorÇakal, Beytullah
dc.contributor.authorOmaygenç, Mehmet Onur
dc.contributor.authorİbişoğlu, Ersin
dc.contributor.authorBoztosun, Bilal
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:58:22Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:58:22Z
dc.date.issued2017
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalı
dc.descriptionWOS: 000405215800001
dc.descriptionPubMed ID: 28440067
dc.description.abstractObjectives: We aimed to evaluate the peri-procedural success of DESolve bio-resorbable scaffolds (BRSs) and analyzed real-life data about major cardiac events during 1-year follow-up. Background: There is little information about real-life data of DESolve BRS which is a novel stent technology offering various advantages over drug eluting stents and commonly used in daily cardiology practice. Methods: We conducted this single-center and non-randomized cross-sectional study from June 2015 through August 2016 in Medipol University Department of Cardiology and included 117 patients undergoing single or multivessel percutaneous coronary interventions (PCI) with novolimus-eluting BRS devices (152 scaffolds) (Elixir Medical Corporation). Study end points were acute device and procedural success, scaffold thrombosis and major adverse cardiac event (MACE) rates of DESolve BRS. Results: Device success was 96.7% and procedural success was 99.3%. We detected MACE rate as 0.9% while clinical-driven target lesion revascularization was performed in one patient. None of the patients experienced scaffold thrombosis or death. Peri-procedural complications were reported in three patients. Conclusions: High rates of successful scaffold implantations, low rates of peri-procedural complications, and major cardiac events in long-term suggest that DESolve scaffolds can safely and effectively be used in daily intervention practice by particularly experienced operators.
dc.identifier.citationGüneş, H. M., Gökdeniz, T., Kızılırmak Yılmaz, F., Demir, G. G., Güler, E., Güler Babür, G. ... Boztosun, B. (2017). Real-life data regarding acute procedural success and 1-year clinical outcome of desolve bioresorbable scaffolds. Journal of Interventional Cardiology, 30(3), 189-194. https://dx.doi.org/10.1111/joic.12386
dc.identifier.doi10.1111/joic.12386
dc.identifier.endpage194
dc.identifier.issn0896-4327
dc.identifier.issn1540-8183
dc.identifier.issue3
dc.identifier.scopusqualityQ2
dc.identifier.startpage189
dc.identifier.urihttps://dx.doi.org/10.1111/joic.12386
dc.identifier.urihttps://hdl.handle.net/20.500.12511/3157
dc.identifier.volume30
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofJournal of Interventional Cardiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectDesolve BRS
dc.subjectDevice Success
dc.subjectMajor Cardiac Events
dc.titleReal-life data regarding acute procedural success and 1-year clinical outcome of desolve bioresorbable scaffolds
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
gokdeniz-tayyar(2017).pdf
Boyut:
342.75 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text